Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trifarotene - Galderma/Mayne Pharma

Drug Profile

Trifarotene - Galderma/Mayne Pharma

Alternative Names: AKLIEF; CD-5789

Latest Information Update: 23 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galderma
  • Developer Galderma; Mayne Pharma Group
  • Class Antiacnes; Antineoplastics; Benzoic acids; Keratolytics; Pyrrolidines; Retinoids; Skin disorder therapies; Small molecules
  • Mechanism of Action Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ichthyosis
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Acne vulgaris
  • Phase II Ichthyosis
  • No development reported Cutaneous T-cell lymphoma

Most Recent Events

  • 20 Dec 2019 Galderma anticipates the national marketing authorisations across concerned European member states in 2020
  • 20 Dec 2019 Galderma receives a positive outcome through the European decentralised procedure for trifarotene approval in Acne
  • 01 Nov 2019 Registered for Acne vulgaris (In adolescents, In children, In adults) in Canada (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top